gip (3-30)
Peptideexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2017 (NCT03702660)
Timeline
Indications
Studied for
Mechanism of action
GIPR agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06934473 | N/A | May 21, 2025 | University of Copenhagen |
| NCT06208904 | N/A | Mar 1, 2024 | University of Copenhagen |
| NCT06368752 | Early Phase 1 (Phase 1) | May 4, 2023 | University of Copenhagen |
| NCT05375968 | Phase 2 | Feb 25, 2023 | National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University |
| NCT04792762 | N/A | Jun 12, 2018 | University of Copenhagen |
| NCT03702660 | N/A | Aug 1, 2017 | University of Copenhagen |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 5 | 5 | 2 | 2017 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2023 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1